Arrayit sales and marketing team reports microarray life sciences consumables sale to clinical leader Kephera Diagnostics headquartered in Framingham Massachusetts USA and commercializing products for the rapidly expanding global healthcare markets linkedin.com/in/andrew-levi…
Exactly. Those of us who have been here a long time lived thru the $0.6M worth of notes that they took in 2014-2015 which drove the pps from 0.15 to 0.0001 and the O/S (common shares) from 56M to 1.055B shares. It took 3 years for the pps to recover after the end of the conversions. HOPE that Mark , Rene and Todd have learned from the fiasco, but then again they don't own many common shares (around 1 million). They own preferred shares
Market Data 
Markets 
AI
